| Symbol | COCP |
|---|---|
| Name | COCRYSTAL PHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 19805 NORTH CREEK PARKWAY, BOTHELL, Washington, 98011, United States |
| Telephone | +1 786 459-1831 |
| Fax | — |
| — | |
| Website | https://www.cocrystalpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001412486 |
| Description | Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). Additional info from NASDAQ: |
New Form EFFECT - Cocrystal Pharma, Inc. <b>Filed:</b> 2026-05-01 <b>AccNo:</b> 9999999995-26-001445 <b>Size:</b> 1 KB
Read more(10% Negative) COCRYSTAL PHARMA, INC. (COCP) Announces Delay in vaccines Trials for norovirus Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreCocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
Read moreCocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
Read moreNew Form S-3 - Cocrystal Pharma, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001493152-26-018732 <b>Size:</b> 502 KB
Read more(10% Negative) COCRYSTAL PHARMA, INC. (COCP) Announces Delay in billion Trials for rolling review of a New Drug Application (NDA) Due to Regulatory Process, Manufacturing Considerations, Safety Review
Read moreCocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Read more(10% Negative) COCRYSTAL PHARMA, INC. (COCP) Announces Delay in available Trials for norovirus infection Due to Geopolitical Situation, Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreCocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07198139 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Hea… | Phase1 | Norovirus | Recruiting | 2026-03-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06160531 | Influenza Viral Challenge Study of CC-42344 in Healthy Participants | Phase2 | Influenza A | Completed | 2023-11-25 | 2024-07-18 | ClinicalTrials.gov |
| NCT05977140 | CDI-988 Safety Study in Healthy Participants | Phase1 | Healthy Volunteers | Completed | 2023-09-27 | 2025-07-23 | ClinicalTrials.gov |
| NCT05202379 | CC-42344 Safety Study in Healthy Participants | Phase1 | Influenza A | Completed | 2022-02-11 | 2023-03-29 | ClinicalTrials.gov |
| NCT03501550 | Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) | Phase2 | Chronic Hepatitis C | Completed | 2018-06-26 | 2019-06-07 | ClinicalTrials.gov |
| NCT02760758 | A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects | Phase1 | Hepatitis C | Completed | 2016-04-01 | 2017-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02760758 |
| CDI-31244 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02760758 |
| SOF/VEL | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03501550 |
| CDI-31244 | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03501550 |
| Placebo | Other | Phase PHASE2 | Influenza A | COMPLETED | NCT06160531 |
| CC-42344 | Other | Phase PHASE2 | Influenza A | COMPLETED | NCT06160531 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05977140 |
| CDI-988 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05977140 |
| Snow Mountain Virus | Other | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| Placebo | Other | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| CDI-988 | Other | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| Placebo | Other | Phase PHASE1 | Influenza A | COMPLETED | NCT05202379 |
| CC-42344 | Other | Phase PHASE1 | Influenza A | COMPLETED | NCT05202379 |
| Snow Mountain Virus | OTHER | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| CDI-988 | DRUG | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| CC-42344 | DRUG | Phase PHASE2 | Influenza A | COMPLETED | NCT06160531 |
| SOF/VEL | DRUG | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03501550 |
| Placebo | DRUG | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| CDI-31244 | DRUG | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03501550 |